… therapy (CRT) have been demonstrated to improve clinical outcomes in patients with HF and
reduced left ventricular ejection fraction (LVEF). Improvement in LVEF has been reported to …

… clinically assessed left ventricular ejection fraction (LVEF) and survival in a large, heterogeneous
clinical … , patients in clinical trials may not be representative of clinical practice, and …

Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in
patients with heart failure, reduced ejection fraction (HF–REF), and mild-to-severe symptoms, …

… We sought to determine current practice patterns of LV ejection fraction (LVEF) reassessment
during the months following MI and evaluate the predictors and clinical significance of …

… The prescription rate of MRAs was higher in patients with lower blood pressure and lower
left ventricular ejection fraction at discharge, and the prescription rate of beta-blockers was …

Background: Although strategies for optimization of pharmacologic therapy in patients with
heart failure with reduced ejection fraction (HFrEF) are scripted by guidelines, data from HF …

… preserved ejection fraction to assess areas of agreement and disagreement as well as
gaps in evidence. We anticipate this will improve clinical decision-making and guide future …

… meaningfully from that in clinical trials, particularly the higher prevalence of patients with
preserved left ventricular (LV) ejection fraction (EF) typically excluded from clinical trials, thus …

… COMPETENCY IN SYSTEMS-BASED PRACTICE: A total of 1 in 6 patients with HFrEF
encountered in clinical practice develop worsening HF within 18 months of diagnosis. These …

… left ventricular ejection fraction (HF-REF) may become clinically apparent … clinical trials for
the treatment of HF have primarily included patients with REF (left ventricular ejection fraction […